EGFR and breast carcinoma: In a different study, although the addition of this compound to MCF-7 breast cancer cells in vitro resulted in minimal growth inhibition, when combined with the dual EGFR/HER2 tyrosine kinase inhibitor, GW2974 (Sigma Aldrich), synergistic growth inhibition was observed [33].